Results 41 to 50 of about 26,462 (230)

Response variability to P2Y12 receptor inhibitors: expectations and reality.

JACC. Cardiovascular interventions, 2013
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity,
Siller-Matula, Jolanta M, Trenk, Dietmar, Schrör, Karsten, Gawaz, Meinrad, Kristensen, Steen D, Storey, Robert F, Huber, Kurt   +6 more
openaire   +4 more sources

Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Journal of Interventional Cardiology, 2021
Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual antiplatelet therapies (DAPTs) after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). Methods.
Yi Xu, Yimin Shen, Delong Chen, Pengfei Zhao, Jun Jiang   +4 more
doaj   +1 more source

GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets. [PDF]

, 2020
G protein-coupled receptors (GPCRs) mediate the majority of platelet activation in response to agonists. However, questions remain regarding the mechanisms that provide negative feedback toward activated GPCRs to limit platelet activation and thrombus ...
Benovic, Jeffrey, Brass, Lawrence F., Chen, Xi, Cooper, Matthew, DeHelian, Daniel, Goldfinger, Lawrence E., Gupta, Shuchi, Ma, Peisong, McKenzie, Steven E., Naik, Meghna U., Naik, Ulhas P., Stalker, Timothy J., Wurtzel, Jeremy G.T., Zhao, Xuefei   +13 more
core   +1 more source

Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]

, 2017
BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence, Behnamfar, Omid, Lin, Felice, Mahmud, Ehtisham, Palakodeti, Samhita, Patel, Mitul P, Pourdjabbar, Ali, Reeves, Ryan R   +7 more
core   +1 more source

Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2017
Antiplatelet therapy with P2Y12-receptor inhibitors has become the cornerstone of medical treatment in patients with acute coronary syndrome treated with percutaneous coronary intervention (PCI). With over 100 million prescriptions filled since its approval, clopidogrel is the most widely used P2Y12-receptor inhibitor.
Winter, MP, Grove, EL, De Caterina, R, Gorog, DA, Ahrens, I, Geisler, T, Gurbel, PA, Tantry, U, Navarese, EP, Siller-Matula, JM   +9 more
openaire   +5 more sources

Systematic review and meta-analysis of optimal P2Y₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome [PDF]

, 2016
Background: Patients with diabetes are at increased risk of acute coronary syndromes (ACS) and their mortality and morbidity outcomes are significantly worse following ACS events, independent of other comorbidities.
Brown, Oliver I, Hoye, Angela, Rossington, Jennifer A   +2 more
core   +2 more sources

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

Leukotriene E4 induces MUC5AC release from human airway epithelial NCI-H292 cells

Allergology International, 2015
Background: Hypersecretion of mucin in the airway epithelium is an important feature of allergic airway diseases. Of the 3 cysteinyl leukotrienes (CysLTs; LTC4 LTD4 and LTE4), only LTE4 is sufficiently stable to be detectable in extracellular fluids ...
Hideaki Shirasaki, Etsuko Kanaizumi, Nobuhiko Seki, Tetsuo Himi   +3 more
doaj   +1 more source

Antiplatelet therapy de-escalation in a patient after percutaneous coronary intervention with a high risk of bleeding

Российский кардиологический журнал, 2023
According to recommendations of ESC 2020-year, de-escalation of therapy with a P2Y12 receptor inhibitor (transition from prasugrel or ticagrelor to clopidogrel) It can be considered as an alternative strategy of dual antiplatelet therapy (DAPT) for ...
A. A. Kassymova, J. A. Mansurova, L. K. Karazhanova, A. A. Chinybayeva   +3 more
doaj   +1 more source